fda warning letters glp-1 compounders september 2025 news Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide FDA issues 30 warning letters

Will the oral GLP-1 pill be safe long-term

Semaglutide Dosing Schedule and Weight Loss Outcomes Clinical evidence from the STEP trials showed that participants receiving 2.4 mg of semaglutide weekly lost an average of 15% of their body weight over 68 weeks, compared to less than 3% in the placebo group

DOI: 10.1001/jamanetworkopen.2026.16951.

Likewise, GLP-1/exendin-4 would contribute to the normalization of the altered levels of these kinases in pathophysiological states such as obesity, for example

Younger patients with lower surgical risk and stable weight may require less interruption

In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space